Navigation Links
TrialCheck(R) Cancer Clinical Trial Matching Interface to Debut on American Cancer Society Web Site
Date:9/10/2007

on between patients and their physicians about clinical trials provides a wonderful tool to help link patients with the right trial for them. As a result, we'll accelerate our understanding of cancer."

Updating Trial Locations in Real Time

Real-time updates are a distinguishing feature of TrialCheck that will also benefit users. In 2006, the Coalition introduced a technology enhancement that imports location information upon receipt for Cooperative Group trials. Participating oncology practices and hospitals appear in a trial record in real time as they are federally approved to participate in that study; conversely, locations are removed in real time from the database record when the study is closed or no longer available at that site. With outdated location information a common problem among trial databases, real-time updates are a popular feature among TrialCheck users. While real-time updates currently apply only to Cooperative Group studies, the proprietary informatics platform developed for real-time updates is a possible model for the Coalition to replicate with other types of studies in the future (pharmaceutical and biotech companies, cancer centers offering their studies in multiple locations, and other government-sponsored studies).

Tracking Clinical Trial Trends

An innovative TrialCheck feature, TrialTracker, will capture a vivid picture of patients' clinical trial experiences, determining whether they took steps and ultimately were enrolled into a trial. For the first time, the American Cancer Society can gain an expansive view of cancer clinical trial activity generated from its services and patient support initiatives, tracking the experiences of patients individually and collectively. In addition to activity around the thousands of nationally registered cancer clinical trials open and seeking patients in the United States, the TrialTracker service will provide comprehensive reporting on demographics and insights into patient b
'/>"/>

SOURCE Coalition of Cancer Cooperative Groups
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Protox Announces Positive Clinical Data from Prostate Cancer Study
6. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
11. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and PITTSBURGH , Aug. 28, ... today announced that its shareholders have approved Mylan,s ... PRGO ; TASE) and the related issuance of ... extraordinary general meeting of shareholders held today. The ... at the extraordinary general meeting. In addition, the ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de 2015 /PRNewswire/ ... hoy su participación en el  Congreso de la ... cardiológicas más recientes y novedosas, entre ellas HeartModel ... a las personas y la tecnología con los ... diagnosticar, guiar los tratamientos y permitir atención en ...
(Date:8/27/2015)... , Aug. 27, 2015  The Academy of ... and Drug Administration,s (FDA,s) draft guidance and proposed ... and biosimilars, to bear a nonproprietary name with ... been seeking a decision from the FDA on ... health care stakeholders urging the agency to use ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
... Cornerstone Therapeutics Inc. (Nasdaq: CRTX ), a specialty ... primarily for the respiratory and related markets, today announced that ... ET on Tuesday, May 4, 2010 , to ... 31, 2010 .  Management will also provide an update on ...
... International Merchant Advisors, Inc. (Pink Sheets: IMAI) www.imaiinc.com ... Science, Inc., intends to launch a national line of medical marijuana ... in the new CNBC article "Marijuana and Money" www.cnbc.com , ... $109 billion per year. , ...
Cached Medicine Technology:Cornerstone Therapeutics to Host First Quarter 2010 Conference Call 2Cornerstone Therapeutics to Host First Quarter 2010 Conference Call 3International Merchant Advisors to Develop Organic Science Branded Medical Marijuana Product Line 2International Merchant Advisors to Develop Organic Science Branded Medical Marijuana Product Line 3
(Date:8/28/2015)... Church, VA (PRWEB) , ... ... ... Cybersecurity Risk Management for Medical Devices:, Understanding the FDA’s Position and Best ... Rockville, MD, http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally renowned ...
(Date:8/28/2015)... ... ... The 6th Annual Survivor in the City, Chicago silent auction and ... to its cadre of widespread support—an official letter of support and gratitude from the ... community and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain Aneurysm ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ones of a ... struggling with chemical dependency, may be able to find some hope in the ... treatment center for addiction located in Western Michigan. Focusing on several different aspects ...
(Date:8/28/2015)... ... ... “ Frequentz ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... product movement from beginning to end. , Businesses benefit greatly from having the ability ...
(Date:8/28/2015)... Boynton Beach, FL. (PRWEB) , ... August 28, ... ... creating problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new ... Strawbridge believes that it should begin with the employer and employees getting together ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Track Product Movement from Beginning to End with Frequentz 2
... The Centers for Disease Control and Prevention ( ... leading cause of death. In 2009, an estimated ... attack, and about 470,000 will have a recurrent ... of people nationwide focus on education and provide ...
... brings extensive experience in neuroscience and oncology to ... therapeutic categories , , ROCKVILLE, Md. ... Pharmaceutical, Inc. (OAPI), a fast-growing health care company ... North America, has announced the appointment of Mark ...
... Pharmaceutical Services, Inc. (NYSE: WST ) announced ... results before the market opens on Thursday, February 19, ... discuss the results and business expectations at 9:00 a.m. ... (888)790-3758 or (210)839-8398. The passcode is WST.A live broadcast ...
... Additional $2.5 MillionCRANBURY, N.J., Feb. 12 Palatin ... it has received $4.1 million from AstraZeneca relating ... and license agreement to discover, develop and commercialize ... trial sponsored research agreement. Palatin also announced that ...
... discuss fourth quarter financial results -LAVAL, QC, Feb. 12 ... DDSS ) today announced that it will host a ... (ET) to discuss its fourth quarter 2008 financial results. ... via news release at approximately 7:00 a.m. the same ...
... Inc. (OTC Bulletin Board: DORB) (DOR or the Company) ... million partnering agreement with Sigma - Tau Pharmaceuticals, Inc. ... North America of orBec(R) (oral beclomethasone dipropionate or Oral ... make a $6 million upfront investment in DOR, inclusive ...
Cached Medicine News:Health News:The ISSA Offers 8 Tips for American Heart Month 2Health News:Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer 2Health News:Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer 3Health News:Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer 4Health News:Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer 5Health News:Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer 6Health News:West to Host 2008 Fourth Quarter Conference Call 2Health News:Palatin Technologies Announces Receipt of $4.1 Million from AstraZeneca 2Health News:Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET) 2Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 2Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 3Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 4Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 5Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 6Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 7
The Stryker Shoulder Instrumentation Set is ideal for open and arthroscopic shoulder procedures. The kit includes all the necessary tools for bone and tissue preparation as well as suture management ...
... The Arthroscopy Scissor is ideal for excising soft ... debris in the joint. The serrated edge on ... well as hold tissue within the jaws for ... and right jaw curvatures, are the perfect tools ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ... style, size and angle required for large ...
Medicine Products: